Johnson & Johnson and Abbott Laboratories are on opposite trajectories following their latest earnings and major strategic decisions. J&J posted first-quarter Innovative Medicine revenue of $15.43 billion, up 11.2%, driven by DARZALEX at $3.96 billion and TREMFYA jumping 68.3%, while STELARA fell 59.7% against biosimilars. Abbott’s second-quarter Medical Devices revenue reached $5.85 billion, up 9%, with FreeStyle Libre at $2.19 billion, and Diagnostics surged 42.3% after the $21 billion Exact Sciences acquisition added $919 million from Cologuard. J&J raised full-year revenue guidance to $100.3 billion to $101.3 billion and adjusted EPS to $11.45 to $11.65, while Abbott lifted its EPS range to $5.45 to $5.60 but saw interest expense jump from $50 million to $299 million. J&J is spinning off its Orthopaedics unit within 18 to 24 months, while Abbott is integrating Exact Sciences. Year to date, J&J shares are up 23.63% and Abbott is down 18.16%, with J&J trading at a forward P/E of 22 and Abbott at 18.
Abbott LaboratoriesAbbott's EPS guidance raised but interest expense surged from $50M to $299M, and shares down 18.16% YTD.
Johnson & JohnsonJ&J raised full-year revenue and EPS guidance, with Innovative Medicine revenue up 11.2% and shares up 23.63% YTD.
NVIDIA Corporation